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Abstract
Antibodies are currently the fastest-growing class of therapeutics. Although naked antibodies have 
proven valuable as pharmaceutical agents, they have some limitations, such as low tissue 
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penetration and a long circulatory half-life. They have been conjugated to toxic payloads, PEGs, 
or radio-isotopes to increase and optimize their therapeutic efficacy. Although nonspecific 
conjugation is suitable for most in vitro applications, it has become evident that site specifically 
modified antibodies may have advantages for in vivo applications. Herein we describe a novel 
approach in which the antibody fragment is tagged with two handles: one for the introduction of a 
fluorophore or 18F isotope, and the second for further modification of the fragment with a PEG 
moiety or a second antibody fragment to tune its circulatory half-life or its avidity. Such 
constructs, which recognize Class II MHC products and CD11b, showed high avidity and 
specificity. They were used to image cancers and could detect small tumors.
Keywords
enzymes; isotopic labeling; PEGylation; positron emission tomography; single-domain antibodies
The success of immunotherapies, such as the application of monoclonal antibodies against 
the immune checkpoint inhibitors CTLA4 and PD-1 on T cells and PD-L1 on their targets 
cannot be viewed separately from the contributions of myeloid cells, which are often present 
at the tumor margin, and express Class II MHC and/or CD11b products. Macrophages can 
affect tumor growth by establishing either a detrimental or a favorable microenvironment. 
Thus, the ability to image myeloid cells presence is of diagnostic relevance and, compared 
to tumor-specific markers,[1] may be a more generally applicable approach for detection of 
tumor cells.[2,3] A commonly used minimally invasive clinical diagnostic approach is the 
use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), which 
distinguishes areas of high metabolic activity, such as tumors, from surrounding tissue with 
lesser glucose uptake.[4] These methods do not usually provide information on immune cells 
in the tumor microenvironment. There are now tools to track immune cells, by the use of 
isotopically labeled anti-CD11b, anti-Class-II-MHC, and anti-CD8 antibody fragments.[5–7]
The comparatively large size of intact full-sized antibodies results in a long circulatory half-
life, and may also hinder efficient tissue penetration.[8] These considerations have driven the 
search for smaller antibody-derived formats as alternative imaging tools.[1,6] We generated 
camelid single-domain antibody fragments (VHHs) as the smallest antigen-binding 
derivatives obtainable from naturally occurring antibodies.[9] VHHs lend themselves to 
enzymatic modification and have been used in a variety of applications, including 
imaging.[10]
The relationship between the affinity and valency of the antibodies or their fragments, and 
their suitability for various imaging applications has received scant attention.[1,11] The 
production of bivalent single-domain antibodies based on their monovalent equivalents 
could address issues of avidity, while retaining desirable properties, such as small size. For 
example, the bivalent derivatives of single-domain antibodies might still be small enough to 
penetrate tissues, be rapidly cleared from the circulation, yet benefit from increased avidity. 
On the other hand, tuning of the circulatory half-life could improve the efficiency with 
which VHHs stain their targets. The attachment of small PEG groups could be used as a tool 
to “tune” the persistence of a VHH in the circulation. Moreover, PEGylation can decrease 
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the immunogenicity of VHHs, which is important in cases in which repeated administration 
is required; however, in rare cases even the PEG functionality itself has been suggested to be 
immunogenic.[12]
Structures of VHHs show that their C terminus is positioned away from the antigen-binding 
site.[13] We therefore chose a chemical approach to link two fully functional VHHs through 
their C termini to ensure that their antigen-binding capacity would not be compromised by 
modification of one of the N termini in the resulting fusion, and that the two binding sites 
thus created would be truly equivalent, which would be more difficult to ascertain for 
genetic fusions.
Four sortase substrates were designed and synthesized for the production of dimers or 
PEGylated VHHs (Figure 1). The substrates either contained two bioorthogonal handles or a 
handle and a fluorophore. An Alexa647-labeled substrate, 2, was designed in such a way 
that the reaction products could be used in fluorescence-activated cell sorting (FACS) 
experiments to estimate relative in vitro binding affinities; a substrate modified with Texas 
Red, 3, was designed to enable two-photon microscopy and the estimation of relative in vivo 
binding affinities; and a trans-cyclooctene-modified substrate, 4, was produced to enable 
rapid installation of a 18F-labeled-tetrazine radioactive tag for positron emission tomography 
(PET; 18F t1/2 < 2 h). The dimers were produced accordingly (Figure 2; see also the 
Supporting Information).
For DC8 (anti-Class-II), splenocytes were stained with different concentrations of 
monomers and dimers and analyzed by FACS. For DC13 (anti-CD11b), the CD11b+ 
mutuDC dendritic cell line was used. For Class II MHC and CD11b, the VHH dimers were 
found to bind approximately 3.3- and 2.3-fold more strongly than the corresponding 
monomers, respectively (Figure 3).
We next evaluated the in vivo binding characteristics of the VHH dimers versus monomers. 
Due to the more abundant expression of Class II MHC molecules on splenocytes as 
compared to that of CD11b, we explored the in vivo binding affinity of anti-Class-II dimers. 
Mice were injected intravenously (i.v.) with equal amounts of monomers and dimers (0.25 
nmol) of DC8. The mice were euthanized 2 h postinjection (p.i.), and lymphoid organs were 
excised for examination. The monomers and dimers yielded different staining patterns 
(Figure 3B). The dimer showed interspersed yet more pronounced staining than the 
monomer, thus corroborating the FACS results.
To render monomers and dimers suitable for immuno-PET, we produced dimer VHHs by 
using substrate 4. To produce the 18F-labeled tetrazine, we applied a method that was 
automated in its key steps to minimize operator radiation exposure in the course of 
preparation (Figure 4A; see the Supporting Information). Next, we produced 18F-labeled 
anti-Class-II and anti-CD11b dimers and used them for PET imaging (Figure 4). PET 
showed that both dimers stained lymphoid organs (Figure 4; see also movies 1 and 2 in the 
Supporting Information). The anti-Class-II-MHC dimer showed stronger staining of 
lymphoid organs, particularly the spleen, as compared to the anti-CD11b dimer (Figure 
4D,F). We attribute this behavior to the fact that in the spleen there are fewer CD11b+ cells 
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than Class II MHC+ cells, and less CD11b expressed per cell. We established specificity by 
blocking the targets of these VHHs by the introduction of unlabeled VHHs as competitors 
prior to imaging. PET imaging conducted 2 h after the injection of 18F-labeled VHHs 
showed effective blocking of the signals in the lymphoid organs, thus further underlining the 
specificity of the signals (Figure 5C; see also movies 3–6). To further confirm the specificity 
of the dimers in the absence of competing VHHs, we imaged MHC II−/− and CD11b−/− 
mice. We detected no PET signals in lymphoid organs, thus further confirming the 
specificity of both dimers (Figure 4E,G; see also movies 7 and 8).
The monomers and dimers did not differ in uptake into the kidneys and intestine, organs 
commonly targeted nonspecifically by VHHs in the course of their clearance.[14] These 
experiments helped us set the stage to explore the ability of VHH dimers to image tumors. 
We imaged two types of tumors with the developed bivalent VHHs by the engraftment of 
mice with the B16 melanoma or the pancreatic tumor cell line panc02. Both dimers readily 
detected the lymphoid organs as well as the B16 melanoma tumor (see movies 9 and 10) or 
the panc02 graft (see movies 11 and 12). Upon excision, the panc tumors were no more than 
about 1–2 mm in diameter, thus showing the method to be sensitive. Postmortem 
biodistribution analysis also correlated well with the FACS and two-photon results (Figure 
5A,B). Although the dimers stained secondary lymphoid organs more efficiently than their 
corresponding monomers, specifically for the anti-class-II-MHC VHH, the PET signals in 
the tumors showed no commensurate increase (Figure 5A,B). We attribute this observation 
to the larger size of the dimer as compared to the monomer, which may result in lower 
penetration in tumors, thus counteracting the effect of the higher affinity of the dimer.
We examined whether we could manipulate circulatory half-life to further improve the 
signal-to-noise ratio. PEGylation of VHHs results in increased circulatory half-life, and the 
increase correlates with the size of the attached PEG group.[15] VHHs sortagged with 
substrate 2 or 3 were treated with DBCO-functionalized PEG (5, 10, or 20 kDa) to yield the 
final PEGylated VHHs (Figure 2E,F). B6 mice received 5 mg of PEGylated VHH and were 
euthanized 3 h later, followed by dissection of the lymph nodes and spleen for FACS and 
two-photon microscopy. FACS showed a significant increase in staining of the PEGylated 
DC8–Alexa647 versus the non-PEGylated DC8. We observed an approximately 30, 100, 
and 220% increase in staining for 5, 10, and 20 kDa PEG-conjugated DC8, respectively, 
thus establishing a correlation between the size of the attached PEG moiety and staining 
efficiency (Figure 3D). When we injected DC8–Alexa647–PEG (20 kDa), which showed the 
strongest binding in vivo, into a MHC II−/− mouse, FACS analysis showed no staining in the 
spleen (Figure 3D). This result confirmed that PEGylation does not affect the specificity of 
the VHHs.
We then explored the PEGylated VHHs for their suitability for PET imaging. VHH DC8 
was PEGylated and modified with an 18F radionuclide. PEGylated VHHs showed increased 
staining of the lymphoid organs, as confirmed by FACS and two-photon microscopy (Figure 
5D). The longer circulatory half-life of PEGylated VHHs presumably increases the 
likelihood of a VHH binding to its target, as long as target accessibility is not compromised 
by PEGylation. As expected, the 18F-labeled DC8–PEG (20 kDa) had the highest PET 
signal in blood at the time of imaging (3 h p.i.; Figure 5D). Although the larger 20 kDa PEG 
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can significantly increase the staining efficiency in lymphoid organs, it delays circulatory 
clearance, a factor to consider when isotopes with short half-lives, such as 18F or 11C, are 
being used. However, VHHs modified with 10 or 5 kDa PEG still show significantly 
increased staining efficiency and yet can be rapidly cleared. When isotopes with longer half-
lives, such as 89Zr or 64Cu, are used to label VHHs, the use of a 20 kDa PEG moiety should 
improve staining.
In summary, we have developed a method to produce site specifically PEGylated or bivalent 
single-domain antibodies equipped with either a fluorophore or radionuclide (18F) for 
different imaging modalities. The reaction conditions enable full retention of the biological 
activity of the fusion partners. By cytofluorimetry, dimers bind approximately 3 times more 
avidly to their targets. Two-photon microscopy confirmed that bivalent single-domain 
derivatives labeled with Texas Red bind more efficiently to their targets. PEGylated 
fluorescent VHHs showed improved staining in vivo, with larger PEG substituents giving 
stronger signals in FACS. In immuno-PET experiments, bivalent 18F-labeled VHHs stained 
lymphoid organs in vivo more effectively than monomers. 18F-labeled PEGylated VHHs 
showed improved staining, whereby PEG substituents with a higher molecular weight gave 
stronger signals. Finally, immuno-PET of two different models of tumor-bearing mice 
showed that the DC8 dimer and DC13 dimer detected not only lymphoid organs, as 
expected, but also showed the location of ectopic melanoma and pancreatic tumor grafts. 
Overall, this study provides further support for the notion that derivatives of single-domain 
antibodies are a valuable addition to the available imaging and radiodiagnostic toolbox.
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A) Site-specific labeling of VHHs with sortase, which recognizes the “LPXTG” motif and 
replaces the G residue with a substrate containing a NH2-G3 moiety. B) Structures of the 
substrates containing bioorthogonal functionalities. The structures were confirmed by LC–
MS.
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A,B) Synthesis of VHH derivatives. C,D) Characterization of the products. The LC–MS and 
SDS-PAGE analysis for DC13 is shown (see the Supporting Information for DC8). Lane 1 
in (C): marker, lane 2: DC13, lane 3: DC13–DBCO, lane 4: DC13–azide–Texas Red, lane 5: 
DC13–dimer–Texas Red, lane 6: DC13–N3–Alexa647, lane 7: DC13–dimer–Alexa647. E,F) 
PEGylation of VHHs and characterization. Lane 1 in (F): marker, lane 2: DC8–Alexa647–
N3, lane 3: DC8–Alexa647–PEG (5 kDa), lane 4: DC8–Alexa647–PEG (10 kDa), lane 5: 
DC8–Alexa647–PEG (20 kDa). All materials were purified by size exclusion 
chromatography. DBCO = dibenzocyclooctyne.
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A,B) Dimers were able to stain their targets with increased efficiency as compared to the 
corresponding monomers. A) Cells were stained in vitro with the indicated concentrations of 
Alexa647-labeled VHH monomers or dimers. B) Equal amounts of the DC8 monomer and 
DC8 dimer were injected i.v.; the mice were euthanized 2 h p.i., and their spleens were 
excised for two-photon imaging. C) Equal amounts of DC8 with or without PEG, both 
equipped with TexasRed were injected i.v. into mice; spleens were excised 3 h p.i. for two-
photon imaging. D) Equal amounts of DC8 with or without PEG, all equipped with 
Alexa647, were injected i.v. into mice; spleens were excised 3 h p.i., and cells were 
harvested and analyzed by FACS. WT = wild type.
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A) Synthesis of an 18F-labeled tetrazine. DMF = N,N-dimethylform-amide, TEAB = 
triethylammonium bicarbonate. B) 18F labeling of VHH-dimers, VHH monomers, and PEG-
functionalized VHHs. C) Radio-TLC analysis of the 18F-labeling reactions. D–I) Use of 
the 18F-DC8 dimer and 18F-DC13 dimer to detect lymphoid organs and reveal tumors. PET 
images are shown in both coronal and sagittal views for better visualization. CT images are 
provided for better visualization (H1,2). D,E) PET images of WT (D) and class II MHC−/− 
mice (E) 2 h after injection of the 18F-DC8 dimer (see movies S1 and S7 for a 3D 
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visualization). CV: cervical lymph nodes, BM: bone marrow, SP: spleen, GB: gallbladder, 
LV: liver, KD: kidneys, Ints: intestines, BL: bladder, SC: spinal cord. F,G) PET images of 
WT (F) and CD11b−/− mice (G) 2 h after injection of the 18F-DC13 dimer (see movies S2 
and S8 for a 3D visualization). I1,2) Tumor-associated CD11b+ cells (I1) or class II MHC+ 
cells (I2) were visualized by using the 18F-DC13 dimer (I1) or the 18F-DC8 dimer (I2). 
Arrows point at the tumors. In (I2), stars show the lymph nodes (see movies S11 and S12 for 
a 3D visualization). PET scale bars have arbitrary units. Images are representative for 2–4 
mice with similar results.
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A,B) Postmortem biodistribution of 18F-VHHs in all organs. Mice were injected with the 
same amount of either 18F-VHH or the 18F-VHH dimer. The activity in different organs was 
measured 3 h p.i. C) The VHH monomer can block binding of the 18F-VHH dimer. WT 
mice were injected with different amounts of unlabeled DC8, and the 18F-DC8 dimer was 
injected 20 min later (50 μCi/5 μg). PET standardized uptake values (SUVs) for spleen were 
calculated on the basis of PET images acquired 2 h after injection of the 18F-labeled DC8 
dimer (see movies S3–S6 for a 3D visualization). D) WT mice were injected with the same 
amount of different 18F-DC8 derivatives with or without PEG moieties as indicated. The 
activity in different organs was measured 3 h p.i. (see movies S13–S16 for a 3D 
visualization). LN = lymph nodes.
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